Answers are grounded in this paper and cite their sources.
Retrospective cohort study finds higher incidence of pulmonary fibrosis in COVID-19 patients, suggesting long-term monitoring is essential.
The long-term risk of clinical new-onset pulmonary fibrosis (PF) and its various downstream impacts following SARS-CoV-2 infection remain incompletely characterized in existing literature. A retrospective cohort was analyzed using Montefiore Health System electronic health record data over 4.5 years (March 2020—August 2024). Hospitalized and non-hospitalized COVID-19 patients without prior PF diagnosis were matched 1:2 to COVID-19 negative controls. New-onset PF and subsequent downstream impacts were identified by diagnostic ICD-10 codes. Covariate balance was assessed and Fine-Gray subdistribution hazard ratio (sHR) models were used to estimate PF risk and logistic and Poisson regression models were used to assess post-PF secondary outcomes. Sensitivity analyses included multivariable cause-specific Cox proportional-hazard models, inverse probability weighting and analyses using a pre-pandemic historical control. After propensity score matching, both hospitalized COVID-19 patients (sHR = 2.05; 95% CI [1.69–2.4]) and non-hospitalized COVID-19 patients (sHR = 2.33; 95% CI [1.88–2.88]) demonstrated significantly increased risk of PF when compared to COVID-19 negative controls over up to 4.5-year follow-up period. In patients with new-onset PF, prior hospitalization with COVID-19 has associated with higher odds of pneumonia (OR = 4.84 [3.50–6.67]), bronchiolitis (OR = 3.45 [1.12–8.81]), respiratory failure (OR = 3.76 [2.72–5.16]), asthma exacerbation (OR = 2.54 [1.36–4.46]) and COPD exacerbation (OR = 2.91 [1.80–4.58]), whereas non-hospitalized COVID-19 patients exhibited increased odds of pneumonia (OR = 1.98 [1.25–3.06]) and asthma exacerbation (OR = 2.06[1.00–3.86]). Similarly, hospitalized COVID-19 patients showed increased risk of PH (RR = 1.66[1.01–2.71]) and non-hospitalized patients showed an increased risk of PE (RR = 2.68[1.14–6.35]). In a diverse cohort with up to 4.5 years follow-up, we found both hospitalized and non-hospitalized COVID-19 patients have a higher long-term risk of new-onset PF and higher burden of subsequent downstream respiratory complications compared to matched non-COVID-19 controls. These findings demonstrate post-COVID-19 PF as a relevant and clinically significant outcome and suggest the need for long-term surveillance, risk stratification, and targeted intervention.
No takes yet. Share an insight, caveat, or question.
Changela et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: